Atriva Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
Tübingen, Baden-Wurttemberg, Germany
Type:
sample
Technology:
sample
sample
About: Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Atriva Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.